SCHEMBL3714337

SCHEMBL3714337

CC(C)CC(C(=O)O)N(CCc1cncn1Cc1cccc(F)c1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 7/20 0.41
CYP11B2 P19099 7/20 0.41
ACE2 Q9BYF1 4/20 0.40
ACE P12821 3/20 0.40
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
ANPEP P15144 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7381299 0.91 CYP11B1 (0.43) CYP11B1CYP11B2ACE2ACEFNTA
SCHEMBL7422079 0.91 ACE2 (0.45) CYP11B1CYP11B2ACE2ACE
SCHEMBL3704205 0.90 CYP11B1 (0.42) CYP11B1CYP11B2ACE2ACEFNTA
SCHEMBL3710371 0.89 CYP11B1 (0.41) CYP11B1CYP11B2ACE2ACEFNTA
SCHEMBL3681437 0.89 ACE2 (0.48) CYP11B1CYP11B2ACE2ACEFNTA
SCHEMBL7382597 0.89 CYP11B1 (0.53) CYP11B1CYP11B2ACE2ACE
SCHEMBL7230044 0.88 ACE2 (0.41) CYP11B1CYP11B2ACE2ACEFNTA
SCHEMBL7384484 0.86 CYP11B1 (0.41) CYP11B1CYP11B2ACE2ACECYP2D6
SCHEMBL3712509 0.85 ACE2 (0.41) CYP11B1CYP11B2ACE2ACE
SCHEMBL1655465 0.84 ACE2 (0.45) CYP11B1CYP11B2ACE2ACETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010093804-A1 ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS ORE PHARMACEUTICALS, INC. (US) 2010-08-19 WO claimed
JP-2002543120-A 2002-12-17 JP claimed
WO-2000066104-A9 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARM INC (US) 2002-08-29 WO claimed
WO-2002039997-A2 ACE-2 MODULATING COMPOUNDS AND USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-05-23 WO claimed
EP-1183019-A2 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF Millennium Pharmaceuticals, Inc. (US) 2002-03-06 EP claimed
WO-2000066104-A2 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2000-11-09 WO claimed
EP-3717077-A1 METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) 2020-10-07 EP disclosed
WO-2002039997-A2 ACE-2 MODULATING COMPOUNDS AND USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-05-23 WO disclosed
EP-1183019-A2 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF Millennium Pharmaceuticals, Inc. (US) 2002-03-06 EP disclosed
WO-2000066104-A2 ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2000-11-09 WO disclosed